Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices.
Implantable tibial nerve stimulation devices
Neurostimulation
Overactive bladder
Percutaneous tibial nerve stimulation
Tibial nerve stimulation
Urge urinary incontinence
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
26
01
2024
accepted:
01
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
The tibial nerve is an established target for neuromodulation in the management of overactive bladder (OAB) and its associated symptoms, including urge urinary incontinence (UUI). Technologies are currently available to deliver tibial nerve stimulation (TNS) through percutaneous devices or through implantable devices. The benefits and safety of percutaneous TNS have led to it as a guideline-recommended therapy. However, patient compliance is limited by the burden of weekly office visits and the need for maintenance treatments. Further, insurance often only covers a limited number of lifetime visits for percutaneous TNS. These factors and others have led to the development, study, and utilization of implantable TNS devices. Implantable TNS devices deliver the same therapeutic mechanism of action for nerve stimulation with a permanent implanted device that provides at-home stimulation rather than in-office therapy delivery. Additionally, there is an added potential for dynamic and patient-centered stimulation. There is a large body of high-quality evidence published for TNS, including numerous randomized controlled trials published on percutaneous TNS which have consistently demonstrated superior efficacy to sham and similar efficacy to that of anticholinergic medications. Percutaneous TNS also performs better than conservative therapy including pelvic floor muscle training. The percutaneous and implantable approaches deliver nerve stimulation to the same target nerve, using the same mechanism of action. Therefore, data from randomized trials of percutaneous TNS are informative for implantable TNS devices. At the time of this article's publication, at least two implantable TNS devices have received marketing authorization from the Food and Drug Administration (FDA). The objective of this review is to discuss the mechanism of action for TNS and summarize the published literature from clinical trials of percutaneous TNS as a foundation of high-quality evidence for implantable devices targeting the tibial nerve.
Identifiants
pubmed: 38748331
doi: 10.1007/s12325-024-02864-3
pii: 10.1007/s12325-024-02864-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
pubmed: 19941278
doi: 10.1002/nau.20798
Coyne K, Payne C, Bhattacharyya S, Revicki D, Thompson C, Corey R, Hunt T. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health J Int Soc Pharmacoecon Outcomes Res. 2004;7:455–63.
doi: 10.1111/j.1524-4733.2004.74008.x
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.
pubmed: 17049716
doi: 10.1016/j.eururo.2006.09.019
Stewart W, Rooyen JV, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.
pubmed: 12811491
doi: 10.1007/s00345-002-0301-4
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen C-I, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.
pubmed: 24456314
Elstad EA, Taubenberger SP, Botelho EM, Tennstedt SL. Beyond incontinence: the stigma of other urinary symptoms. J Adv Nurs. 2010;66:2460–70.
pubmed: 20735505
pmcid: 3032268
doi: 10.1111/j.1365-2648.2010.05422.x
Aoki Y, Brown H, Brubaker L, Cornu J, Daly J, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042.
pubmed: 28681849
pmcid: 5878864
doi: 10.1038/nrdp.2017.42
D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77.
pubmed: 30681183
doi: 10.1002/nau.23897
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–63.
pubmed: 31039103
doi: 10.1097/JU.0000000000000309
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199:779–84.
pubmed: 28965782
doi: 10.1016/j.juro.2017.09.102
OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence . Accessed 22 Apr 2024
Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8.
pubmed: 15698871
doi: 10.1016/j.ucl.2004.09.004
de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52.
pubmed: 9426749
doi: 10.1016/S0090-4295(97)00587-6
Al-Danakh A, Safi M, Alradhi M, Almoiliqy M, Chen Q, Al-Nusaif M, Yang X, Al-Dherasi A, Zhu X, Yang D. Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines. Parkinson’s Dis. 2022;2022:2700227.
Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromodul Technol Neural Interface. 2023. https://doi.org/10.1016/j.neurom.2023.03.017 .
doi: 10.1016/j.neurom.2023.03.017
Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–9.
pubmed: 3057221
doi: 10.1016/S0022-5347(17)42038-6
Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PEV, van KPEV. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352–7.
pubmed: 10411037
doi: 10.1016/S0022-5347(05)68558-8
Cooperberg M, Stoller M. Percutaneous neuromodulation. Urol Clin N Am. 2005;32(71–8):vii.
Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol-Ren Physiol. 2011;300:F385–92.
doi: 10.1152/ajprenal.00526.2010
Choudhary M, Mastrigt R, Asselt E. Effect of tibial nerve stimulation on bladder afferent nerve activity in a rat detrusor overactivity model. Int J Urol. 2016;23:253–8.
pubmed: 26690557
doi: 10.1111/iju.13033
Choudhary M, van Mastrigt R, van Asselt E. Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats. Springerplus. 2016;5:35.
pubmed: 26835217
pmcid: 4713404
doi: 10.1186/s40064-016-1687-6
Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. Int Urogynecol J. 2020;31:865–70.
pubmed: 31853597
doi: 10.1007/s00192-019-04186-3
Rahnamai MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler J. 2020;26:1274–80.
doi: 10.1177/1352458519894714
Kobashi K, Nitti V, Margolis E, Sand P, Siegel S, Khandwala S, Newman D, MacDiarmid SA, Kan F, Michaud E. A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. Urology. 2019;131:77–82.
pubmed: 31199966
doi: 10.1016/j.urology.2019.06.002
Harding, Lapitan M, Arlandis S et al (2023) EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-neurogenic-Female-LUTS-2023.pdf .
Chermansky C, Schurch B, Rahnamai M, Averbeck M, Malde S, Mancini V, Valentini F, Sahai A. How can we better manage drug-resistant OAB/DO? ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S46–55.
pubmed: 31821628
Marcelissen T, Cornu J-N, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, Rieken M, Rahnama’i MS. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? [Figure presented]. Eur Urol Focus. 2018;4:760–7.
pubmed: 29807823
doi: 10.1016/j.euf.2018.05.004
Apostolidis A, Averbeck M, Sahai A, Rahnama’i M, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–93.
pubmed: 28444708
doi: 10.1002/nau.23170
Gordon T, Merchant M, Ramm O, Patel M. Factors associated with long-term use of percutaneous tibial nerve stimulation for management of overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2021;27:444–9.
pubmed: 32649325
doi: 10.1097/SPV.0000000000000911
Jung CE, Menefee SA, Diwadkar GB. Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence. Int Urogynecol J. 2021;32:617–25.
pubmed: 32572541
doi: 10.1007/s00192-020-04325-1
te DMJ, J.P.F.A. H, van BMR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39:702–6.
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–99.
pubmed: 28196724
doi: 10.1016/j.eururo.2017.01.037
Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018. https://doi.org/10.1136/bmjopen-2018-021889 .
doi: 10.1136/bmjopen-2018-021889
pubmed: 30467131
pmcid: 6252764
Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee K-S, Sahai A, Wein AJ, Andersson K-E. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:PHARMREV-AR-2021-000523.
eCoin summary of safety and effectiveness data. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036B.pdf . Accessed 1 Dec 2023.
eCoin physician manual. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036D.pdf . Accessed 1 Dec 2023.
ReviTM patient therapy guide. https://bluewindmedical.com/wp-content/uploads/2023/10/revi-patient-therapy-guide.pdf . Accessed 28 Nov 2023.
Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin
pubmed: 33797291
doi: 10.1097/JU.0000000000001733
Lee UJ, Xavier K, Benson K, et al. Rationale and design of an implant procedure and pivotal study to evaluate safety and effectiveness of Medtronic’s tibial neuromodulation device. Contemp Clin Trials Commun. 2023;35: 101198.
pubmed: 37691849
pmcid: 10491630
doi: 10.1016/j.conctc.2023.101198
Govier F, Litwiller S, Nitti V, Kreder Jr K, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8.
pubmed: 11257669
doi: 10.1016/S0022-5347(05)66469-5
eCoin peripheral neurostimulator system patient manual. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036C.pdf . Accessed 28 Nov 2023.
Finazzi-Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, Sciobica F, Marfia GA. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28:320–4.
pubmed: 19090588
doi: 10.1002/nau.20651
Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, MacDiarmid SA. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.
pubmed: 20171677
doi: 10.1016/j.juro.2009.12.036
Finazzi-Agr E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184:2001–6.
doi: 10.1016/j.juro.2010.06.113
Lashin A, Eltabey N, Wadie B. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. Int Urol Nephrol. 2021;53:2459–67.
pubmed: 34601705
doi: 10.1007/s11255-021-02999-0
Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M, Italy A. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2016;43:121–6.
doi: 10.1590/s1677-5538.ibju.2015.0719
Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.
pubmed: 19616802
doi: 10.1016/j.juro.2009.05.045
Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75:230–4.
doi: 10.1159/000350216
Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, Hanzal E. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6.
pubmed: 26073262
doi: 10.1016/j.ejogrb.2015.05.014
Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol Off J Braz Soc Urol. 2018;44:102–8.
doi: 10.1590/s1677-5538.ibju.2016.0611
Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017;24:8838–46.
pubmed: 28646940
MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a fully-implanted, nickel-sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence. J Urol. 2019;201:967–72.
pubmed: 31009968
doi: 10.1016/j.juro.2018.10.017
Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I M, et al. Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn. 2022;41:539–51.
pubmed: 35032328
doi: 10.1002/nau.24864
Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R, Yu O, Crane P, Larson E. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.
pubmed: 25621434
pmcid: 4358759
doi: 10.1001/jamainternmed.2014.7663
An F, Yang X, Wang Y, Chen J, Wang J. OAB epidemiological survey of general gynaecology outpatients and its effects on patient quality of life. Neurourol Urodyn. 2016;35:29–35.
pubmed: 25307534
doi: 10.1002/nau.22659
Zillioux J, Welk B, Suskind A, Gormley E, Goldman H. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41:1928–33.
pubmed: 36066046
doi: 10.1002/nau.25037
Du C, Berg W, Siegal A, Huang Z, Jeong R, Hwang K, Kim J. Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology. 2021;153:119–23.
pubmed: 33581232
doi: 10.1016/j.urology.2021.02.005
Malde S, Marcelissen T, Vrijens D, Apostilidis A, Rahnama’I S, Cardozo L, Lovick T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn. 2020;39(Suppl 3):S96–103.
pubmed: 32662561